Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
VPA-exposed SD rats exhibited a significant increase in marble-burying behavior compared to the control group ( P 0.05 )
(2018) 42:e13846
Based on the working hypothesis of P-gp-dependent collateral sensitivity [14,15,16,17], we examined the ability of tamoxifen as a collateral sensitivity drug for two reasons: a) tamoxifen has been previously shown to activate P-gp ATPase at clinically achievable concentration (46 M) [20, 21], and b) tamoxifen is widely used in the treatment of estrogen receptor-positive breast cancer [22]
10.1038/s41380-020-0645-4 Mol
Product Specifications Compound: CJC-1295 with DAC Class: Synthetic GHRH analog with albumin-binding modification Origin: Modified GHRH (1-29) analog with N-terminal Drug Affinity Complex Molecular Weight: ~3647 Da Form: Lyophilized powder Vial Size: 5mg in 3mL glass vial Purity: 99%+ verified by HPLC and mass spectrometry (See COAs) Research Background CJC-1295 with DAC has been investigated in research literature across several scientific contexts: GHRH receptor pharmacology investigations into receptor binding kinetics, signal transduction, and cellular response mechanisms in pituitary cell models Albumin-binding peptide research studies examining how covalent serum albumin binding via maleimidopropionic acid modification affects peptide half-life, distribution, and stability properties Peptide half-life engineering analytical chemistry research on extended-duration peptide analogs and the structural modifications that enable prolonged biological activity Comparative GHRH analog research studies positioning CJC-1295 with DAC alongside other modified GHRH peptides (including Sermorelin and Tesamorelin) in cellular research contexts Structure-activity relationships peptide chemistry research on how DAC modification affects receptor binding affinity compared to non-modified GHRH analogs Cellular signaling pathway research investigations into GHRH receptor activation and downstream cellular signaling cascades CJC-1295 with DAC was originally developed by ConjuChem Biotechnologies as part of their broader Drug Affinity Complex peptide research platform, which utilized albumin-binding chemistry to extend peptide half-life across multiple research compound development programs
